Investor's Watch: Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

Henrietta Brewer
April 6, 2017

(CYCC) in which JMP Securities Downgrades Cyclacel Pharmaceuticals, Inc. 12,529,875 shares of the stock traded hands. Annual EPS Growth of past 5 years is -10.40%. In phrases of Market analysis and buying and selling signals, RSI moving above the horizontal 30 reference standard is regarded as a bullish indicator, at the same time as the RSI transferring under the horizontal 70 reference standard is visible to be a bearish indicator.

Organizations that control a large sum of money, like insurance companies, pension funds or mutual funds and buy stocks are called "institutional investors".

Cyclacel Pharmaceuticals, Inc. got Initiated on 16-Oct-15 where investment firm H.C. Wainwright Initiated the stock to Buy.


Stock is now moving with a positive distance from the 200 day simple moving average of approximately 68.02%, and has a solid year to date (YTD) performance of 54.44% which means the stock is constantly adding to its value from the previous fiscal year end price. The Stock Market opened sessions at 7.95 and closed at 8.17. The company reported the earnings of $-0.69/Share in the last quarter where the estimated EPS by analysts was $-0.73/share. Out of rating recommendations 0 have given the stock a Buy while 1 recommend the stock as Outperform. Also, the Hold rating count is 0 as of 04/04/17. The Company's shares were trading 87.26% above their 50-day moving average and 68.02% above their 200-day moving average.

An important factor to consider when evaluating a stock's current and future value are the 52 week price high and low levels. For the quarter, shares are performing at -33.20%. The stock hit its 52-week high price on 08/22/16 and 52-week low price on 11/08/16. The monthly stock performance comes in at 1.81%. Transactions were down -10.69% as firms now own 64.20% of the company stock.

While taking a glance at financials, we can look at a number of key indicators.


"We believe these findings further validate the potential utility of CYC140 and its selection as a clinical candidate", said Spiro Rombotis, President and Chief Executive Officer of Cyclacel Pharmaceuticals. Presently, it has a Return on Equity (ROE) of -79.60% and Return on Investment (ROI) of -85.10%. The average numbers of shares are traded in a security per day, during the recent 3-month period. Beta value of the stock stands at 2.99.

The company's quick ratio for most recent quarter is 3.70. Total debt to equity ratio of the company for most recent quarter is 0.00 whereas long term debt to equity ratio for most recent quarter is 0.00.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER